6026 results about "Efficacy" patented technology

The AI-enhanced cellular modeling and simulation platform is a computational system designed to enhance biomedical research and development and personalized medicine and wellness. This platform integrates simulation modeling, machine learning and artificial intelligence, multi-omics data, and sophisticated data fusion and decision-support techniques to create comprehensive models of cellular systems and processes across multiple scales. It enables researchers and clinicians to simulate complex biological interactions, predict disease progression, and design or optimize treatment strategies or medical devices with improved accuracy and efficacy. The system's architecture allows for integration of various components, including real-time data processing, federated learning, and quantum computing enhancements. From personalized drug discovery and cancer therapies to synthetic biology and epidemiological analysis, this platform offers powerful tools for understanding and manipulating cellular systems and bioengineered systems. By bridging the gap between molecular-level interactions between cells and materials and organism-wide effects, it enables significant advancements in healthcare and biological sciences.

The invention relates to the technical field of cardiovascular disease treatment, and discloses a cardiovascular disease medical decision support method based on a large model, and the method comprises the steps: obtaining multi-modal cardiovascular disease medical data, constructing a multi-source heterogeneous data set, carrying out the preprocessing and feature fusion, and constructing a combined representation model based on the pre-training large model and the fusion of traditional and western medicine knowledge. And designing a hierarchical space-time diagram convolutional network to generate a dynamic physiological state code of the patient, and constructing a multi-target optimization decision tree to generate a treatment scheme containing western medicines, traditional Chinese medicine prescriptions and non-drug intervention. A federal learning framework is adopted to cooperatively train a local model, data security is guaranteed, a global model is optimized, and a curative effect attribution module is further arranged to correct decision deviation. According to the method, multi-modal data and traditional Chinese and western medicine knowledge are integrated, personalized treatment scheme generation is achieved, data safety is guaranteed, and the cardiovascular disease diagnosis and treatment level is improved.

The invention relates to the technical field of clinical experiment data processing, and discloses a clinical experiment data analysis method based on reinforcement learning, and the method comprises the steps: obtaining time sequence physiological parameters and treatment scheme execution state parameters; performing hierarchical feature extraction on the time sequence physiological parameters, constructing a dynamic response feature model, and generating an initial treatment response evaluation model in combination with the execution state parameters; loading risk constraints and curative effect indexes to generate a comprehensive evaluation model, and simulating to obtain strategy regulation and control data; constructing and training a reinforcement learning decision model, and generating a treatment path correction model and initial treatment parameters; obtaining dynamic strategy adjustment information, and constructing a multi-stage optimization model for iterative optimization to obtain optimal treatment path parameters; reasoning a curative effect standard reaching probability based on a real-time model, and adjusting a strategy to realize dynamic curative effect matching. According to the method, the clinical data dynamic analysis and treatment scheme optimization capability is improved, and the method is suitable for precise medical scenes.

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.

The invention relates to the technical field of physical sign monitoring, in particular to a physical sign parameter monitoring method accompanying the medication process of a severe mental disease patient. According to the method, the dynamic change of the physical sign parameters is captured by acquiring the physical sign parameter time sequence curves of the to-be-monitored patient in the two stages before and after medication. For each time sequence curve, data value differences and fluctuation duration are analyzed, and abnormal fluctuation data segments are identified. Furthermore, a historical normal time sequence curve is utilized to determine a historical normal fluctuation section corresponding to the abnormal fluctuation, and the overall state of the physical sign parameters is visually reflected through comparative analysis and calculation of a stable index. Meanwhile, the physical sign condition of the patient is monitored by combining the stability index of the same physical sign parameter before and after medication and the time sequence characteristics of the abnormal fluctuation data segment. According to the method, the physical sign state of the patient is reflected more accurately by comparing the change of the physical sign parameters of the patient with the historical normal condition, and data support with higher credibility is provided for doctors to carry out medicine effect judgment or illness state analysis.

Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. A balance of precision and recall can be applied to at least one of a toxicity-related model or an efficacy-related model to configure immunotherapy treatment of a patient and / or cohort of patients. Model output can be evaluated differently depending on a determine patient selection criterion to trigger different actions.

The invention discloses a multi-modal fusion-based traditional Chinese medicine recommendation method, system and device and a medium, and the method comprises the steps: constructing a heterogeneous graph according to a core representative object and preprocessed traditional Chinese medicine multi-modal data; inputting the heterogeneous graph into a graph neural network for data fusion to obtain traditional Chinese medicine multi-modal fusion data; constructing a knowledge graph based on the traditional Chinese medicine multi-modal fusion data to obtain a traditional Chinese medicine knowledge graph; segmenting the traditional Chinese medicine knowledge graph into sub-graphs processed by multiple agents according to the drug effect and the drug use safety, and obtaining a medicinal material sub-graph associated with a drug effect agent and a safety sub-graph associated with a safety agent; based on the medicinal material sub-graph and the safety sub-graph, collaborative iteration optimization is carried out through a medicinal material combination strategy and a medicinal material safety checking strategy to select medicinal materials, and an optimal compound recommended by the traditional Chinese medicine is obtained; and inputting the optimal compound into the fine-tuned large language model, and determining a target compound recommended by the traditional Chinese medicine. The accuracy of traditional Chinese medicine recommendation can be improved.

The invention provides a compound DOTA-HX2-DZ and application thereof, and belongs to the technical field of biological medicine. According to the invention, the molecular structure of DZ-HX2-DOTA is optimized, and a special connexon is designed and adopted, so that the problem of limited anti-tumor curative effect caused by poorer stability, fat solubility, tumor residence time and other properties of a radiolabeled drug in the prior art is solved. The compound provided by the invention can significantly reduce the risk of label removal of radioactive metal ions in an in-vivo environment, and ensures that the compound stably plays a role at a targeted part; the compound has excellent molecular lipid solubility, can penetrate cell membranes and vascular barriers more easily, improves the bioavailability of drugs, prolongs the in-vivo circulation time, prolongs the tumor residence time, and further improves the treatment efficiency. The DZ-HX2-DOTA disclosed by the invention has broad-spectrum tumor targeting property, and can be used for diagnosing and treating various types of malignant tumors.

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

The invention belongs to the field of medical chemistry, and particularly relates to a crystal form of a heterocyclic compound and a pharmaceutical composition thereof. Specifically, the invention relates to a crystal form of 4-((2R, 3S, 5R)-3-(3, 4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl) thiacyclopentane-2-formamido) pyridine-2-formamide and a pharmaceutical composition of the crystal form of 4-((2R, 3S, 5R)-3-(3, 4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl) thiacyclopentane-2-formamido) pyridine-2-formamide. The crystal form is good in crystallinity, excellent in chemical stability and crystal form stability, high in process safety and capable of playing a good drug effect in various animal models.

The invention relates to a drug delivery carrier based on extracellular vesicles and application thereof.The drug delivery carrier contains extracellular vesicle scaffold protein and recombinant membrane fusion protein, the recombinant membrane fusion protein comprises a first fragment and a second fragment, the amino acid sequence of the first fragment is shown as SEQ ID NO: 5, and the amino acid sequence of the second fragment is shown as SEQ ID NO: 6; the second fragment has n amino acids, the sequence of the second fragment is the sequence of the first n amino acids at the N end of the amino acid sequence as shown in SEQ ID NO: 7, and n is an integer between 50 and 200. According to the drug delivery carrier disclosed by the invention, the efficiency of releasing drug active molecules before reaching lysosome is remarkably improved, and the drug effect of extracellular vesicle drugs can be improved.

The invention relates to the technical field of biological medicines, in particular to a sulfonamide compound for treatment and an enantiomer thereof as well as a preparation method and application thereof, and has the beneficial effects that the provided sulfonamide compound and the enantiomer thereof have the characteristics of strong stability, longer action effect, better drug effect and the like; the compound is a better diuretic and new anti-encephaledema medicine.

The invention belongs to the technical field of drug screening, and provides a multi-target drug screening and optimizing method based on machine learning, which comprises the following steps: S1, carrying out feature screening on compound molecular descriptors by utilizing a machine learning algorithm, and determining the molecular descriptor which has the most significant influence on biological activity; s2, constructing a quantitative structure-activity relation model, and predicting the biological activity of the compound; s3, based on a multi-objective optimization algorithm, combining absorption, distribution, metabolism, excretion and toxicity properties of the compound; according to the method, feature screening is carried out on compound molecule descriptors by utilizing a machine learning algorithm, a QSAR model is constructed to predict the biological activity, ADMET property classification prediction is combined, the biological activity, ADMET properties and pharmacokinetic characteristics of drugs are comprehensively considered, and the accuracy and accuracy of drug activity prediction are improved. The method can efficiently and accurately screen and optimize drug candidate compounds with potential drug effects and good pharmacokinetic characteristics, so that the success rate of drug research and development is increased, and the research and development cost and time are reduced.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine prescription efficacy quantification method and system.The method comprises the steps that chemical component spectrums, pharmacodynamic substance contents and biological activity indexes of traditional Chinese medicines forming a prescription are obtained; constructing a multi-target regulation and control network by combining a traditional Chinese medicine-target interaction database according to the chemical component spectrum, the pharmacodynamic substance content and the biological activity index, identifying a core efficacy pathway cluster by adopting a Louvain algorithm, and calculating a pathway activation intensity value by adopting a pathway target membership weighting model; according to the core efficacy pathway cluster, establishing a mapping relation between the core efficacy pathway cluster and traditional Chinese medicine efficacy terms through ontology and semantic mapping, and according to pathway activation intensity values, generating a prescription efficacy intensity vector through a weighted aggregation model; according to the efficacy intensity vector of the prescription, verifying and correcting the network weight through an in-vitro cell model, and generating the efficacy quantification of the prescription in combination with the clinical syndrome calibration coefficient. Therefore, the problems of single data dimension and insufficient quantification result accuracy in the prior art are solved.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

The invention provides a traditional Chinese medicine meridian prescription system based on multi-omics integration analysis of extracellular vesicles, and the system comprises a data collection module which is used for collecting biopsy sample information of different groups of individuals based on related experiments and literatures of traditional Chinese medicine meridian prescription treatment; the data processing module is used for obtaining and preprocessing extracellular vesicle data and intestinal flora data based on biopsy sample information; the multi-omics integration module is used for obtaining multi-omics integration data; the discovery and verification module is used for obtaining the potential menstrual prescription drug effect evaluation biomarker and performing experimental verification on the potential menstrual prescription drug effect evaluation biomarker to obtain a verification result; and the system biology application module is used for obtaining a regulatory mechanism of the extracellular vesicles in a biological system based on construction of a gene-protein-metabolite interaction network. The invention can comprehensively reveal the pharmacodynamic mechanism of the traditional Chinese medicine menstrual prescription, and provides strong technical support and application prospect for the modern, scientific and internationalized development of traditional Chinese medicines.

The invention discloses an AI-driven disease diagnosis and curative effect monitoring analysis system, which comprises a data processing module used for collecting multi-source diagnosis and treatment data and constructing a multi-modal sample set; the diagnosis prediction module is used for generating a diagnosis label, a diagnosis confidence value and a prediction curative effect trend through a multi-task learning model; the curative effect comparison module is used for collecting actual curative effect data, constructing a curative effect observation sequence and generating a curative effect deviation sequence based on the curative effect observation sequence and the predicted curative effect trend; the credibility evaluation module is used for executing credibility review based on the curative effect deviation sequence and the diagnosis confidence value; and the path evolution module is used for recording continuous multi-round diagnosis correction results, generating a jump type diagnosis path and updating a diagnosis and treatment data chain. The dynamic closed-loop verification mechanism between the multi-mode diagnosis and treatment data and the predicted curative effect trend improves the accuracy of disease diagnosis, the reliability of curative effect prediction and the adaptability of the diagnosis and treatment process.

The invention relates to the field of medical information management, in particular to a children malignant tumor treatment process and follow-up visit electronic management system and a children malignant tumor treatment process and follow-up visit electronic management method. The method comprises the steps that the body surface area of a patient is calculated, and the chemotherapy drug dosage in each cycle is calculated based on the body surface area of the patient; performing cycle-by-cycle accumulation on the chemotherapeutic drug dose in each cycle to obtain an actual accumulated dose; calculating and standardizing the specific numerical value of each curative effect index based on the actual accumulated dose, and calculating a comprehensive therapeutic effect score by combining the importance weight of each curative effect index; and calculating the disease-free survival rate based on the actual accumulated dose and the comprehensive treatment effect score. The problems that at present, most medicine dosage calculation methods neglect the special physiological features of children, a treatment monitoring system lacks dynamic adjustment support in the treatment process, a follow-up management system is insufficient in quantitative analysis capacity for long-term prognosis, and personalized long-term health management suggestions cannot be provided for patients are solved.

The invention provides a PET tracer precursor compound as well as a preparation method and application thereof, and also discloses a < 68 > Ga-labeled PET tracer, the PET tracer precursor compound is simple in preparation method, short in preparation time and high in radiochemical yield, and has the advantages of good in-vivo and in-vitro stability, high specificity, high intake and the like; the tumor or inflammation part can be accurately and stably detected and positioned; the Ga-68 labeled targeted PARP-1 radioactive probe synthesized on the basis of the compound Olaparib can realize qualitative diagnosis of PARP-1 in tumors, further realizes non-invasive accurate quantification of PARP-1 in tumors, provides a reliable basis in stages of clinical staging, treatment decision, curative effect monitoring and the like, and finally realizes accurate diagnosis and treatment.

The invention relates to the technical field of electronic prescriptions, in particular to a dynamic electronic prescription generation method and system based on artificial intelligence. The method comprises the following steps: collecting the latest physiological state parameter flow of a patient, carrying out real-time health state evaluation, and generating a personalized patient state map; historical medical records of a patient are extracted, time sequence pathological evolution tracking is carried out, and a pathological evolution trajectory is generated; performing multi-parameter time sequence difference comparison calculation and drug curative effect quantitative evaluation based on the personalized patient state map and the pathological evolution trajectory to obtain a curative effect evaluation report; performing allergic drug identification on the patient based on the historical medical record of the patient, and performing secondary drug screening to obtain a drug candidate set; and performing intelligent matching calculation on the drug candidate set according to the curative effect evaluation report, and performing combinatorial optimization analysis to generate a final effective electronic prescription. The electronic prescription is automatically updated and adjusted based on the state change of the patient, the risk of allergic prescriptions is reduced, and the safety of the prescriptions is improved.

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor(s) determining that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in an electronic health record (EHR) system communicatively coupled to the one or more processors. The processor obtains descriptive information relating to a patient. The processor selects a pharmacokinetic model. The processor applies the pharmacokinetic model and utilizes the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection. The processor generates rankings for the drug therapies and determines if the current drug regimen comprises a probability above a threshold. The processor generates a new order.

The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.

The invention provides a drug relocation method and a drug relocation system. The method comprises the following steps: predicting an expression profile of a drug after cell line disturbance according to a chemical structure of the drug, dose information of the drug and an undisturbed expression profile. And calculating the differential expression profile of the gene in the cell line based on the expression profiles before and after the cell line is disturbed by the drug. And for each drug, according to the differential expression profiles of the genes, calculating an average value of the differential expression profiles of the genes after the drugs disturb different cell lines, and sorting the genes based on the average value to obtain a sorting list of the differential expression profiles of the drugs. And according to the gene characteristics of the target disease and the sorting list, calculating the enrichment score of each drug on the target disease, and according to the enrichment score, evaluating the potential efficacy of the drug on the target disease. The drug relocation method provided by the invention can be used for giving disease specific gene characteristics for drug library screening.

The invention discloses a multi-effect repair type collagen and application thereof, and belongs to the technical field of synthetic biology. Transdermal peptide TD-1, a transmembrane region of human XVII type collagen, an extracellular sixteenth non-collagen region, an extracellular fifteenth collagen region and a coding gene of a His tag are selected to be connected in series, and a gene sequence is optimized through pichia pastoris codon selection preference; and then the T-COL17R3 is constructed and expressed to obtain the T-COL17R3. Efficacy experiments prove that compared with similar products sold in the market, T-COL17R3 not only has excellent transdermal performance, but also has better cell proliferation and migration promoting capability, better capability of resisting early saccharification product ketoamine and later saccharification product dicarbonyl compounds, better capability of scavenging free radicals and resisting elastase, and can be used for preparing the anti-epidermal drug. In addition, synthesis of melanin in B16-F10 cells can be reduced, so that T-COL17R3 has excellent application potential in development of pharmaceutical compositions or skin care products with repairing, anti-wrinkle and firming or whitening and brightening effects.

The invention relates to the technical field of knowledge maps, in particular to a multi-task hepatitis B drug screening method and system based on knowledge map assistance, and the method comprises the following steps: based on hepatitis B virus genotype sequence data recorded along with time, patient drug use records and drug sensitivity. According to the method, virus genotype sequence data, patient drug use records, drug sensitivity and other multi-dimensional dynamic time sequence data are integrated, interaction events between entities are marked through timestamps, and virus variation tracks, drug curative effect changes and other dynamic characteristics are embedded into atlas node attributes; and the knowledge representation can reflect the time dependence in a real scene. A hyperedge connection multi-entity set is defined based on biological pathway annotation information and protein interaction data, the limitation that only a binary relation is supported in a traditional knowledge graph is expanded, a drug combination and multi-target synergistic effect mechanism is explicitly modeled, and misjudgment of the combination effect caused by simplification of the interaction relation is avoided.

The invention relates to a bionic exosome for anti-inflammation and repair as well as a preparation method and application thereof, and belongs to the field of cosmetics. The bionic exosome provided by the invention comprises a membrane structure and an internal load phase, the membrane structure comprises a phospholipid bilayer, a stabilizer and a targeting ligand; the internal load phase comprises a solvent and an active component; the phospholipid bilayer is composed of phospholipid compounds; preferably, at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound, and at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound; at least one of cholesterol, phytosphingosine and sodium stearoyl glutamate is preferably adopted as a stabilizer, so that the stabilizer of the obtained bionic exosome is improved, and the bionic exosome has the advantages of high encapsulation efficiency, good encapsulation efficiency stability, simplicity in operation, excellent anti-inflammatory and repairing effects and the like.

The invention discloses application of chrysin-7-0-beta-D-glucuronide in treatment of ischemic heart disease or an LRP6 inhibitor, and belongs to the technical field of treatment of ischemic heart disease. The invention provides a new application of a small molecular compound chrysin-7-0-beta-D-glucuronide, the compound realizes regulation and control on a cardiac muscle cell cycle by inhibiting LRP6, and finally promotes repair of cardiac muscle cells and inhibits apoptosis. According to the invention, by exploring the function of inhibiting LRP6 protein of a small molecule drug, a powerful repair reaction is guided after myocardial ischemia reperfusion, so that effective treatment of myocardial infarction is realized. Therefore, finding of an LRP6 inhibitor not only has a potential curative effect on promoting myocardial cells to enter a cell cycle, but also has important significance on treatment of MI.

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The invention relates to the technical field of medical informatics, in particular to a knee osteoarthritis traditional Chinese medicine treatment scheme optimization method based on big data analysis, and the method comprises the following steps: based on knee joint load distribution data, collecting knee joint shear stress data, monitoring cartilage stress gradient data, and calculating a stress peak value in a gait cycle; and obtaining a knee joint biomechanical load balance value. According to the method, by combining shear stress, cartilage stress gradient and gait cycle stress peak value calculation, individual biomechanical characteristics are accurately described, patellar tendon stretching and quadriceps femoris tendon displacement data are analyzed, the instantaneous elastic modulus is recognized, tendon adaptability adjustment measurement precision is improved, soft tissue elastic change is reflected, and by means of individualized stress characteristic data, the stability of the muscle tendon is improved. Abnormal data are eliminated, illness state analysis is optimized, the curative effect evaluation accuracy is improved, the rehabilitation training intensity is dynamically optimized according to the curative effect offset degree, the therapeutic scheme is more adaptive, and the curative effect predictability and the personalized level are improved.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.